Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2712)	1/29/2001 10:41:11 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

I missed the CC - I'll comment later when I get a chance to listen to the archived version. At first glance, this is a somewhat strange patient population to begin with - mild to moderate disease already on (low dose) methotrexate. That may account for no ACR50 numbers mentioned. Also strange that the induction/bi-weekly did worse than the induction/monthly, both on the ACR score and on CRP levels. On the positive side, the safety looked excellent, which is important because this drug has lots of potential uses outside RA. (Hopefully they aren't dependent on the concomitant use of methotrexate as is Enbrel). More after I catch the CC. Peter